Why Ashmore Group plc, GlaxoSmithKline plc, Keller Group plc & GKN plc Look Set To Charge Higher!

Royston Wild explains why Ashmore Group plc (LON: ASHM), GlaxoSmithKline plc (LON: GSK), Keller Group plc (LON: KLR) and GKN plc (LON: GKN) provide unbelievable value for money.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at four London beauties due for a positive re-rating.

Ashmore Group

I believe that shares in Ashmore (LSE: ASHM) are due for a bounce as conditions in key emerging market improve. The business has suffered from weakened client activity over the past year, but with cyclical problems now abating and the financial services play boosting its exposure to new regions — Ashmore recently announced it will apply for a licence to invest directly in the Saudi Arabian stock market — I expect profits to march steadily higher.

The City expects Ashmore to see earnings rise 9% in the year ending June 2015, creating a P/E multiple under the benchmark of 15 times that indicates decent value, at 14.1 times. And despite a projected 4% dip next year the firm still boasts a decent multiple of 14.9 times. On top of this, estimated dividends of 17.1p per share for this year and 17.8p for 2016 create jumbo yields of 5.8% and 6%.

GlaxoSmithKline

Pharmaceuticals giant GlaxoSmithKline (LSE: GSK) has pulled out all the stops to transform its R&D pipeline and battle the ongoing problem of patent expirations across key drugs. The Brentford firm has a terrific record of getting its product from lab bench to pharmacy shelf, assuaging fears over the long-term impact of exclusivity losses, while growing healthcare demand from developing territories should further boost revenues growth in my opinion.

Despite these factors, GlaxoSmithKline remains an absurdly-undervalued stock in my opinion, even though a predicted 16% earnings slip this year creates a slightly-high P/E multiple of 17.3 times. Indeed, an expected 10% rebound in 2016 jolts the ratio to just 15.4 times. And the pills play’s pledge to pay out a dividend of 80p per share for the next three years produces a market-mashing yield of 5.8%.

Keller Group

I am convinced that Keller (LSE: KLR) should enjoy stellar profits growth as construction activity ratchets through the gears. In particular, Keller has brilliant exposure to the US — around two-thirds of group earnings are generated from this territory — and is confident in the outlook for the world’s number one economy, exemplified by the $40m acquisition of North American diaphragm wall builder GeoConstruction just last month.

Despite Keller’s brilliant growth record, the market still seems to have underpriced the London business, and expected expansion of 15% and 12% in 2015 and 2016 correspondingly creates ultra-attractive P/E multiples of 12.2 times and 11 times. And Keller’s cheapness is illustrated by PEG numbers below the value yardstick of 1 through to the close of next year. And for income hunters, predicted payouts of 27.4p per share for this year and 29.9p for 2016 create handy yields of 2.7% and 2.9%.

GKN

With engineer GKN’s (LSE: GKN) core operations firmly in the sweet spot of automobile and aircraft construction, I believe that earnings are poised to surge higher in the years ahead. The Redditch firm is a major supplier to blue-chip manufacturers across the world, and just this month secured a long-term contract with Boeing to supply parts for its 737 MAX, 777X and 787 Dreamliner planes.

Overhanging problems in the defence and agricultural spaces are expected to push earnings 8% lower in 2015, although this still leaves GKN dealing on a dirt-cheap P/E ratio of 12.7 times. And a predicted 11% rebound next year drives this figure to just 11.6 times. Meanwhile, projected dividends of 8.9p and 9.6p per share for these years create tasty yields of 2.5% and 2.7% respectively, sweetening the investment case.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild owns shares of GKN. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »